Physician profile
Daniel P Hexter
NPI 1942224753
$34,780.52
in general payments reported to CMS, 2019-2025
88 companies · $5,253 in 2025
The $5,253 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,739 · 2020: $3,177 · 2021: $5,131 · 2022: $5,639 · 2023: $5,527 · 2024: $5,315 · 2025: $5,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Consulting Fee: $150 · Education: $34.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,910.77 |
| Consulting Fee | $150.00 |
| Education | $34.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,584.55 | 2019-2025 | |
| Biogen, INC. | $3,416.21 | 2019-2025 | Tysabri, Vumerity, Avonex |
| Novartis Pharmaceuticals Corporation | $2,357.94 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,972.66 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Amgen INC. | $1,699.52 | 2019-2025 | Uplizna, Aimovig |
| Pfizer INC. | $1,367.29 | 2021-2025 | |
| Genentech USA, INC. | $1,282.97 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Allergan, INC. | $1,151.46 | 2019-2022 | |
| Lilly USA, LLC | $1,131.07 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Csl Behring | $1,079.29 | 2019-2025 | Hizentra |
| Ucb, INC. | $1,008.05 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Argenx US, INC. | $946.42 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Grifols USA, LLC | $865.21 | 2019-2025 | Gamunex-C |
| Neurocrine Biosciences, INC. | $814.08 | 2019-2025 | Ingrezza, Ongentys |
| Alexion Pharmaceuticals, INC. | $597.54 | 2019-2025 | Ultomiris |
Show all 88 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hexter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.